Trials / Completed
CompletedNCT05200286
A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment
A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- F2G Biotech GmbH · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
A single oral dose study to investigate the PK and safety of olorofim in subjects with severe renal impairment compared to subjects with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olorofim | Single oral dose |
Timeline
- Start date
- 2022-02-10
- Primary completion
- 2022-12-13
- Completion
- 2022-12-13
- First posted
- 2022-01-20
- Last updated
- 2023-01-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05200286. Inclusion in this directory is not an endorsement.